These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23618503)

  • 1. Does enhanced CT influence the biological GTV measurement on FDG-PET images?
    Vera P; Modzelewski R; Hapdey S; Gouel P; Tilly H; Jardin F; Ruan S; Gardin I
    Radiother Oncol; 2013 Jul; 108(1):86-90. PubMed ID: 23618503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
    Vera P; Ouvrier MJ; Hapdey S; Thillays M; Pesquet AS; Diologent B; Callonec F; Hitzel A; Edet-Sanson A; Ménard JF; Jardin F; Tilly H
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1943-52. PubMed ID: 17694309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers.
    Thomas L; Lapa C; Bundschuh RA; Polat B; Sonke JJ; Guckenberger M
    Radiother Oncol; 2015 Aug; 116(2):269-75. PubMed ID: 26364886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
    Yu J; Li X; Xing L; Mu D; Fu Z; Sun X; Sun X; Yang G; Zhang B; Sun X; Ling CC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1468-74. PubMed ID: 19464822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer.
    Bassi MC; Turri L; Sacchetti G; Loi G; Cannillo B; La Mattina P; Brambilla M; Inglese E; Krengli M
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1423-6. PubMed ID: 17931795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study.
    Brændengen M; Hansson K; Radu C; Siegbahn A; Jacobsson H; Glimelius B
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e439-45. PubMed ID: 21641122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma.
    Xu W; Yu S; Ma Y; Liu C; Xin J
    Nucl Med Commun; 2017 Mar; 38(3):259-265. PubMed ID: 28118260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
    Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineation of small mobile tumours with FDG-PET/CT in comparison to pathology in breast cancer patients.
    Hapdey S; Edet-Sanson A; Gouel P; Martin B; Modzelewski R; Baron M; Berghian A; Forestier-Lebreton F; Georgescu D; Picquenot JM; Gardin I; Dubray B; Vera P
    Radiother Oncol; 2014 Sep; 112(3):407-12. PubMed ID: 25216573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Houry S; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):340-5. PubMed ID: 16168829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
    An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
    Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
    Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
    Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.